Features Pricing Learn Reverse Splits Tracker Shelf & ATM Tracker Warrant Tracker PIPE Deal Tracker Weekly Report FAQ API Sign In →
32 /100
MEDIUM RISK
Score updated Oct 13, 2026

CGEM — Cullinan Therapeutics, Inc. Dilution Risk Tracker

Track CGEM dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track CGEM — Get alerts when the score changes →

As of October 13, 2026, Cullinan Therapeutics, Inc. (CGEM) has a DilutionWatch DilutionScore of 32/100, rated MEDIUM dilution risk. Cullinan Therapeutics, Inc. has a market capitalization of $962.10M, 64.35M shares outstanding, 174 institutional holders tracked.

This page includes automatically generated factual summaries from DilutionWatch data. It is not financial advice, not investment research, and not a recommendation. Do your own research. Read the full disclaimer and terms of service.

Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
25
📊 Float Risk
30
⚠️ Warrant Exposure
40
🔄 Convertible Debt
15

Dilution Forecast

☀️
Clear
No significant dilution signals
model est. 0%
No significant dilution signals detected for CGEM.
🔔 Track CGEM — Get forecast alerts →

Market Data

Market Cap$962.10M
Shares Outstanding64.35M
Float44.27M
Cash$334.54M
Debt$2.38M
Short InterestN/A

Source-Backed Evidence Depth

This public preview uses stored DilutionWatch fields and linked SEC/market records only. Missing values are not estimated.

FieldCurrent ValueBasis
DilutionScore32/100DilutionWatch score record
Shares Outstanding64.35MVerified float table or market cache
Public Float44.27MVerified float table or market cache
Market Cap$962.10MMarket data cache
Cash Runway22.5 monthsDilutionWatch score inputs
Shelf CapacityNone in current score inputsSEC-derived dilution fields
ATM CapacityNone in current score inputsSEC-derived dilution fields
Outstanding WarrantsNone in current score inputsSEC-derived dilution fields

Recent source-backed SEC insight records available on this page: 6.

Recent SEC source mix: 4 5, XBRL 1.

The page does not infer future share issuance, financing probability, cash needs, management intent, or price impact when source fields are absent.

Institutional Holdings

QoQ: ↑ 7.7% shares (2026Q1 vs prior)
174 institutional holders · 71.93M shares
#1 Lynx1 Capital Management LP 8.96M shares
#2 MPM BIOIMPACT LLC 7.65M shares
#3 BVF INC/IL 5.75M shares
+ 17 more holders Sign up free to view →

Institutional holder totals are aggregated from ownership filings and may use a different share basis or reporting date than public float. They are not a reconciliation against tradeable float.

Short Interest

Short Interest7.63M
Days to Cover5.1
% of Float17.2%
FINRA data as of Sep 30, 2026

Recent SEC Activity

xbrl XBRL CONVERTIBLE 2022-11-14
4 INSIDER TRANSACTION 2026-03-09
4 INSIDER TRANSACTION 2026-02-26
4 INSIDER TRANSACTION 2026-02-25
4 INSIDER TRANSACTION 2026-02-25
Full SEC filing analysis available with free account →

Recent News

No recent news available for this ticker.

Factual CGEM Dilution Snapshot

Cullinan Therapeutics, Inc. (CGEM) has a DilutionScore of 32/100, rated Medium dilution risk. Score date: October 13, 2026.

This automatically generated snapshot is assembled from stored DilutionWatch data fields and may contain data-source errors or omissions. It is not financial advice, not investment research, and not a recommendation. Do your own research and review the full disclaimer and terms of service.

DilutionScore History — Last 90 Days

CGEM's DilutionScore is currently 32/100 (Medium risk), with 2 score changes tracked over 89 days. The score deteriorated from 35/100 (Medium risk).

Period Score Risk Level Duration
Aug 22 – Oct 13, 202632/100MEDIUM53 days
Aug 14 – Aug 21, 202635/100MEDIUM7 days
Jul 16 – Aug 13, 202632/100MEDIUM29 days

Score recalculated daily from SEC filings and market data. Sign up free for real-time score change alerts.

Share Dilution History

CGEM shares outstanding have increased 4.0% from 59.08M (Mar 2026) to 61.45M (May 2026). Each increase represents potential dilution to existing shareholders.

Date Shares Outstanding Public Float Change
May 08, 202661.45M44.27M▲ 2.15%
May 04, 202661.45M43.34M▲ 0.30%
Mar 14, 202659.08M43.21M▲ 3.95%
Mar 09, 202659.08M41.57M▼ 0.24%

Share counts sourced from verified regulatory filings. Increases indicate dilution events.

Track CGEM Dilution Risk in Real-Time
DilutionWatch monitors SEC filings 24/7 and alerts you the moment CGEM files a shelf registration, ATM offering, warrant notice, or convertible note. Free tier available — no credit card required.
Start Tracking CGEM — Free
Email alert within minutes of any SEC filing Daily DilutionScore™ recalculation Score history & trend tracking Tracks 8,000+ tickers simultaneously

Related Stocks — MEDIUM Risk

Other MEDIUM dilution risk stocks tracked by DilutionWatch with similar profiles:

→ Biotech / Pharma sector dilution risk overview

Browse all 8,490+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
More Research for CGEM
CGEM FDA Catalyst Timeline & Biotech Grade — BiotechSigns

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.